Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39)

Vladan Vucinic, MD, Sabine Leiblein, PhD, Kristina Schakols, MD, Claudia Nehring, MD, Yvonne Remane, PhD, Madlen Jentzsch, MD, Sebastian Schwind, MD, Wolfram Pönisch, MD, Runa Stiegler, MD, Constanze Kliem, MD, Michael Cross, PhD, Dietger Niederwieser, MD

Blood (2018) 132 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2018-99-118531

Published: 2018

Journal Articles

Mobilization of Allogeneic Peripheral Blood Stem Cells in Family Donors with Single-Dose Pegfilgrastim.

Vladan Vucinic, Nadezda Basara, Runa Stiegler, Kristina Bartsch, Constanze Kliem, Sabine Leiblein, PhD, Dietger Niederwieser

Blood (2009) 114 (22): 2148.

https://doi.org/10.1182/blood.V114.22.2148.2148

Published: 2009

Journal Articles

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Chiara Gentilini, MD, Matthias Haegele, Arne Muessig, MD, Axel Nogai, MD, Constanze Kliem, MD, Kristina Bartsch, MD, Nadezda Bazara, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek, Wolfgang A. Bethge, MD

Blood (2007) 110 (11): 2988.

https://doi.org/10.1182/blood.V110.11.2988.2988

Published: 2007

Journal Articles

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

Chiara Gentilini, MD, Urte Hilbers, Volker Huppert, Christoph Loddenkemper, MD, Arne Müßig, MD, Constanze Kliem, MD, Thoralf Lange, MD, Nadezda Basara, Marcus Uhrberg, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek

Blood (2007) 110 (11): 354.

https://doi.org/10.1182/blood.V110.11.354.354

Published: 2007

Journal Articles

Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.

Chiara Gentilini, MD, Urte Hilbers, Goetz Hartung, MD, Thoralf Lange, MD, Constanze Kliem, MD, Ute Hegenbart, MD, Mathias Zeis, MD, Volker Huppert, Bertram Glass, Marcus Uhrberg, Norbert Schmitz, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek

Blood (2005) 106 (11): 2906.

https://doi.org/10.1182/blood.V106.11.2906.2906

Published: 2005

NARROW

Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39)

Mobilization of Allogeneic Peripheral Blood Stem Cells in Family Donors with Single-Dose Pegfilgrastim.

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39)

Mobilization of Allogeneic Peripheral Blood Stem Cells in Family Donors with Single-Dose Pegfilgrastim.

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only